RCM-1
(Synonyms: 2-((2-氧代-2-(噻吩-2-基)乙基)硫基)-4,6-二(噻吩-2-基)吡啶-3-腈) 目录号 : GC33117RCM-1 is a nontoxic inhibitor of Forkhead box M1 (FOXM1) that suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. RCM-1 decreases carcinogenesis and nuclear β-catenin.
Cas No.:339163-65-4
Sample solution is provided at 25 µL, 10mM.
RCM-1 is a nontoxic inhibitor of Forkhead box M1 (FOXM1) that suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. RCM-1 decreases carcinogenesis and nuclear β-catenin.
[1] Lifeng Sun, et al. Sci Signal. 2017 Apr 18;10(475):eaai8583. [2] Samriddhi Shukla, et al. Mol Cancer Ther. 2019 Jul;18(7):1217-1229.
Cell experiment: | Rd76-9 rhabdomyosarcoma, B16-FlO melanoma, H2122 lung adenocarcinoma, 4T1 breast carcinoma, MyC-CaP prostate carcinoma and KPC-2 pancreatic carcinoma cells are seeded in 6-well plates and incubated overnight. The cells are treated with 20 μM concentration of RCM-1 for 24, 48 and 72 h and cell growth is analyzed by counting alive cells using trypan blue. Cells treated with DMSO are used as controls[1]. |
Animal experiment: | Mice[1]Mouse Rd76-9 rhabdomyosarcoma cells (1×106 cells) are injected intramuscularly in the flanks of C56Bl/6J mice (n=8 mice per group). Seven days after the tumor cells inoculation, 40 μL of either Vehicle (DMSO) or RCM-1 (20 mg/kg body weight) are injected intraperitoneally in the animals every other day. The animals are sacrificed and tumors are harvested on day 16. RCM-1 treatment decreases Rd76-9 tumor growth as compared to the DMSO-treated group. Mouse B 16-FlO melanoma cells (1×106 cells) are injected subcutaneously in C56Bl/6J mice (n=7 animals per group). Three days after the tumor cell inoculation, 40 μL of either Vehicle (DMSO) or RCM1 (20 mg/Kg body weight) are injected intraperitoneally in the animals every other day. The animals are sacrificed and tumors are harvested on day 12[1]. |
References: [1]. ARYL SULFONOHYDRAZIDES.WO2018057550A1. |
Cas No. | 339163-65-4 | SDF | |
别名 | 2-((2-氧代-2-(噻吩-2-基)乙基)硫基)-4,6-二(噻吩-2-基)吡啶-3-腈 | ||
Canonical SMILES | N#CC1=C(C2=CC=CS2)C=C(C3=CC=CS3)N=C1SCC(C4=CC=CS4)=O | ||
分子式 | C20H12N2OS4 | 分子量 | 424.58 |
溶解度 | DMSO : 16.67 mg/mL (39.26 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3553 mL | 11.7763 mL | 23.5527 mL |
5 mM | 0.4711 mL | 2.3553 mL | 4.7105 mL |
10 mM | 0.2355 mL | 1.1776 mL | 2.3553 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet